Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the management team will present at the 35^th Annual Piper Sandler Healthcare Conference on Tuesday, November 28, 2023, and will participate in one-on-one meetings with investors throughout the day, in New York, NY.

Presentation Details:

Date: Tuesday, November 28, 2023

Time: 10:10 a.m.-10:30 a.m. EST

Location: Lotte New York Palace, 455 Madison Ave, New York, NY 10022

About Tvardi Therapeutics

Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company has now initiated three Phase 2 clinical programs in hepatocellular carcinoma (NCT05440708), metastatic breast cancer (NCT05384119), and idiopathic pulmonary fibrosis (NCT05671835). To learn more, please visit the website for Tvardi Therapeutics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231121231967/en/